Fluxome and GlycaNova join forces to bring a promising beta glucan product to the US dietary supplement market
Stenlose, Denmark: 15 March 2010 - Nutraceutical ingredient provider, Fluxome A/S has entered a strategic exclusivity agreement with research-based biotechnology company GlycaNova Norway AS. Fluxome gains the exclusive rights from GlycaNova to market and sell a very promising beta glucan product in the US dietary supplement market.
The final product, Fluxome® Beta Glucan, developed by GlycaNova, is a natural beta glucan product manufactured by fermentation. The product has been subject to a number of clinical trials, which confirm Fluxome® Beta Glucan's immune-enhancing effects in humans.
The unique production process enables Fluxome to supply a standardized product with a guaranteed content of completely intact beta glucan.
More info on the press release or Fluxome's website.
Next > Neosens has been rewarded with the first prize during the CFIA 2010 Innovation Award Previous > Avantium wins GPEC 2010 Clean Technology Business Award |
